MINNEAPOLIS, August 29, 2025 — Phraxis announced the successful completion of the first-ever commercial case using its EndoForce Anastomotic Connector. The procedure, performed in the United States, marks the official start of commercial adoption of this FDA-approved vascular access device, designed to simplify the creation of arteriovenous grafts for patients with advanced kidney disease requiring dialysis.
Science Significance
The EndoForce Connector represents a significant scientific breakthrough in vascular access technology. By enabling a precise and reproducible graft-to-vein connection, it replaces traditional hand-sewn sutures and minimizes tissue trauma. The innovation holds promise for improving graft patency, ensuring longer-lasting access, and reducing the risks associated with conventional surgical techniques.
Regulatory Significance
The device’s FDA approval earlier this year validated its safety and effectiveness as the first approved connector for endovascular venous anastomosis. This regulatory success highlights the importance of innovative devices in expanding treatment options for dialysis patients while ensuring compliance with stringent clinical standards..
Business Significance
Advertisement
The first commercial use signals a pivotal moment for Phraxis as it transitions from development to market launch. This milestone strengthens the company’s vascular access portfolio and positions it as a leader in the field of medical device innovation. The commercial rollout paves the way for broader adoption, offering growth opportunities in the U.S. healthcare market.
Patients’ Significance
For patients requiring dialysis, the EndoForce Connector offers the potential for fewer complications and more reliable long-term access. Its design reduces the complexity of surgical procedures, which may lower the need for repeat interventions, improve treatment continuity, and ultimately enhance quality of life for those managing chronic kidney disease.
Policy Significance
The commercial adoption of the EndoForce Connector aligns with healthcare policy goals focused on standardization, safety, and efficiency. By simplifying surgical vascular access and reducing variability in outcomes, the device supports broader objectives of cost-effective care delivery and innovation-driven improvements in chronic disease management.
Transaction Highlights
The first commercial case of the EndoForce Anastomotic Connector represents the beginning of U.S. market adoption following FDA approval. The milestone confirms the device’s clinical readiness and underscores its potential to become a standard in vascular access procedures. Phraxis will continue to expand availability of the connector in healthcare facilities, supported by post-approval monitoring to ensure sustained safety, effectiveness, and patient benefit.
Source: Phraxis Inc. Press Release
